Boston Scientific Co. (NYSE:BSX) Shares Sold by Hardman Johnston Global Advisors LLC

Hardman Johnston Global Advisors LLC lessened its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 27.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 256,994 shares of the medical equipment provider's stock after selling 97,550 shares during the quarter. Boston Scientific comprises approximately 0.8% of Hardman Johnston Global Advisors LLC's portfolio, making the stock its 29th biggest holding. Hardman Johnston Global Advisors LLC's holdings in Boston Scientific were worth $21,536,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Eagle Bay Advisors LLC grew its stake in Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 309 shares in the last quarter. First Foundation Advisors bought a new stake in shares of Boston Scientific during the 1st quarter valued at $25,000. Triad Wealth Partners LLC purchased a new stake in Boston Scientific during the 2nd quarter worth about $26,000. Values First Advisors Inc. bought a new position in Boston Scientific in the 3rd quarter worth about $28,000. Finally, Andra AP fonden purchased a new position in Boston Scientific during the 2nd quarter valued at about $29,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Up 1.0 %

Shares of Boston Scientific stock traded up $0.88 during midday trading on Wednesday, reaching $86.42. 6,203,806 shares of the company's stock traded hands, compared to its average volume of 6,101,743. The company has a market cap of $127.26 billion, a PE ratio of 71.42, a price-to-earnings-growth ratio of 2.46 and a beta of 0.79. The stock has a 50 day moving average of $84.35 and a 200-day moving average of $78.74. Boston Scientific Co. has a 12 month low of $50.84 and a 12 month high of $88.79. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.41%. The company had revenue of $4.21 billion for the quarter, compared to analysts' expectations of $4.04 billion. During the same quarter in the previous year, the company earned $0.50 earnings per share. Boston Scientific's quarterly revenue was up 19.3% on a year-over-year basis. As a group, equities analysts expect that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the sale, the executive vice president now owns 34,748 shares in the company, valued at $2,913,967.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the transaction, the executive vice president now directly owns 34,748 shares of the company's stock, valued at $2,913,967.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $85.00, for a total value of $11,264,795.00. Following the transaction, the executive vice president now directly owns 160,467 shares in the company, valued at $13,639,695. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 309,270 shares of company stock valued at $26,196,718 in the last 90 days. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Bank of America boosted their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Stifel Nicolaus boosted their price target on shares of Boston Scientific from $85.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Needham & Company LLC reiterated a "hold" rating on shares of Boston Scientific in a research report on Thursday, October 31st. Raymond James boosted their target price on Boston Scientific from $91.00 to $94.00 and gave the stock a "strong-buy" rating in a research report on Wednesday, September 4th. Finally, Mizuho upped their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.